Expert Interview
A Second look into the IPF treatment landscape and emerging developmental therapeutics such as PLN-74809
Ticker(s): PLRXInstitution: National Jewish Health
- Associate Professor in the Department of Medicine and Clinic Director of the Interstitial lung disease(ILD) Program at National Jewish Health.
- Sub-investigator for the Phase II study for PLN 74809 as well as numerous other ILD/IPF studies being conducted at National Jewish Health.
- Research focuses on biomarkers in ILD and exercise limitation in post-COVID syndrome, with past research focused on investigating the role of angiogenesis in resolving lung injury and fibrosis.
Can you describe the unmet need in IPF?
Added By: joe_mccannWhat are your feelings on the safety of PLN-74809 thus far, especially given the history of the Biogen program in TGFb? What would you need to see to be confident in the safety of this program?
Added By: joe_mccannHow should we interpret the biomarker data in health volunteers so far? Do you feel this would translate directly to IPF patients?
Added By: joe_mccannIn healthy volunteers what did you make of the spike in inflammation at the 24 hour mark? The company believes this was due to the BAL procedure is that realistic to believe?
Added By: joe_mccannWhat do you make of the company initiating a new Phase 2a trial at a higher dose with a longer duration? Do you think this reflects on the clean safety profile so far or possibly that lower doses and durations are not showing an impact yet?
Added By: joe_mccannOther integrin programs in IPF have stopped development like the AbbVie's program. How confident are you that AvB6/AvB1 is the right target in IPF?
Added By: joe_mccannThe company uses pSMAD2/Smad2 as a biomarker - how reliable is this biomarker for predicting inflammation changes via TGFb?
Added By: joe_mccannIf pSMAD2/Smad2 directly translates to Collagen I why do you think the market is skeptical of this working?
Added By: joe_mccannWhat would a branded agent need to show to get uptake in a now generic IPF landscape? Would you anticipate the use of combination therapy?
Added By: joe_mccannOn a scale of 1-10 how excited are you for this agent?
Added By: joe_mccannAre there any other therapies in the clinic you are interested in? I saw Trevi Therapeutics had some recent data in IPF Cough. Is a cough only therapeutic beneficial to patients?
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
